Optiscan Imaging (OIL.AX) Stock Price
Optiscan Imaging Price
Revenue at Optiscan Imaging has contracted by 12.5% per year over the past 19 years to 448,769.00 AUD. Optiscan Imaging's net margin stands at -1,556.7%, down from -417.9% several years earlier.
Optiscan Imaging stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Optiscan Imaging business model & stock analysis
Frequently asked questions about Optiscan Imaging
The business model of Optiscan Imaging Ltd focuses on developing and commercializing advanced medical imaging technologies. The company specializes in the design and manufacture of confocal laser endomicroscopes, which are used in various medical applications. Optiscan Imaging aims to improve the diagnosis and treatment of diseases through their innovative imaging solutions. By leveraging their expertise in advanced imaging technologies, the company aims to provide healthcare professionals with high-quality and real-time cellular imaging during medical procedures. Optiscan Imaging Ltd's business model is centered around offering cutting-edge medical imaging technologies that deliver precise and detailed cellular imaging for improved patient outcomes.
Optiscan Imaging Ltd is primarily active in the medical technology and healthcare industries.
The main competitors of Optiscan Imaging Ltd in the market include companies such as Carl Zeiss Meditec AG, NIDEK CO., LTD., and Topcon Corporation.
Optiscan Imaging Ltd is a renowned company specializing in medical imaging technologies. Established in [year], Optiscan has achieved significant milestones in the field of diagnostic imaging. The company is known for its innovative optical imaging systems, such as confocal microscopy, which provide high-resolution cellular images for diagnostic purposes. Optiscan Imaging Ltd has a rich history of research and development, consistently striving to push the boundaries of medical imaging. With its advanced imaging solutions, Optiscan continues to contribute to the progression of healthcare.
Optiscan Imaging Ltd has achieved several significant milestones. The company successfully developed and patented a revolutionary confocal endomicroscopy technology, which enables real-time, high-resolution imaging of living tissue. Optiscan Imaging Ltd also received clearance from the U.S. Food and Drug Administration (FDA) for its confocal endomicroscopy system, facilitating its entry into the American market. Furthermore, the company collaborated with renowned medical institutions and researchers worldwide to conduct clinical studies and validate the efficacy of its imaging technology. Optiscan Imaging Ltd's relentless dedication to innovation and research has positioned it as a leader in the field of real-time tissue imaging.
Optiscan Imaging Ltd is primarily present in Australia.
Optiscan Imaging Ltd is a company known for its strong commitment to innovation and excellence in medical imaging. With a vision to improve patient outcomes, Optiscan prides itself on providing cutting-edge solutions for real-time cellular imaging. The company's corporate philosophy revolves around leveraging advanced technology to enhance diagnostic accuracy and enhance the effectiveness of medical procedures. Optiscan Imaging Ltd values integrity, collaboration, and a customer-centric approach, ensuring that their products and services meet the evolving needs of the medical community. By prioritizing research and development, Optiscan aims to revolutionize the field of medical imaging, while maintaining a steadfast dedication to quality and patient care.
Converted at the current exchange rate, the Optiscan Imaging share trades at 0.10 EUR (0.16 AUD).
The Optiscan Imaging share (OIL.AX) is listed on 1 stock exchanges, including: ASX (OIL.AX).
Optiscan Imaging Ltd is a leading provider of high-quality microscope systems and components for scientific research, medical diagnostics, and industrial testing and quality assurance. The company was founded in Melbourne, Australia in 1994 and has since expanded its operations worldwide. Today, Optiscan Imaging is a global company that delivers innovative technologies and products to meet the needs of its customers in various industries.
The revenue of Optiscan Imaging is 448,769.00 AUD. This figure is based on current financial data and reflects the company's business performance.
The profit of Optiscan Imaging is -6.99 M AUD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Optiscan Imaging is currently -23.17. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Optiscan Imaging stock.
The price-to-sales ratio (P/S) of Optiscan Imaging is currently 360.65. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Optiscan Imaging stock.
The Eulerpool Quality Score for Optiscan Imaging is 2/10.
The ISIN of Optiscan Imaging is AU000000OIL4. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Optiscan Imaging is 932111. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Optiscan Imaging is OIL.AX. The ticker symbol is used to trade Optiscan Imaging shares on the stock exchange.
Optiscan Imaging stock
Optiscan Imaging Peer Group
Optiscan Imaging Ticker
Optiscan Imaging FIGI
All fundamentals and in-depth analysis of Optiscan Imaging
Our stock analysis for Optiscan Imaging stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Optiscan Imaging. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.